Home › Burkitt Lymphoma › Ohio
Burkitt Lymphoma clinical trials in Ohio
18 studies for Burkitt Lymphoma are looking for participants at sites in Ohio.
Cities in Ohio
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Cincinnati Children's Hospital, Cincinnati
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Nov 13, 2026 · NCT06173518Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03739814A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- and 3 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT04546399A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 3
Ages 1 and older · All sexes · Updated Nov 12, 2026 · NCT07223021Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Case Western Reserve University, Cleveland
- Cleveland Clinic Foundation, Cleveland
- and 2 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Nov 3, 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- and 2 more
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- and 3 more
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Cleveland Clinic Foundation, Cleveland
RecruitingPhase 2
Ages 18 to 54 · All sexes · Updated Oct 13, 2026 · NCT06918431Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- and 4 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 2 and older · All sexes · Updated May 29, 2026 · NCT05418088Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 1
Ages 1 to 39 · All sexes · Updated Feb 18, 2026 · NCT06863259Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.